Yi Su

1.2k total citations
30 papers, 728 citations indexed

About

Yi Su is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yi Su has authored 30 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Yi Su's work include Cancer-related molecular mechanisms research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and RNA modifications and cancer (3 papers). Yi Su is often cited by papers focused on Cancer-related molecular mechanisms research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and RNA modifications and cancer (3 papers). Yi Su collaborates with scholars based in China, United States and South Korea. Yi Su's co-authors include Jianxun Ding, Xiaodi Li, Qian Li, Yuan Su, Qinyan Yue, Baoyu Gao, Bing Xiong, Yu Chen, James Chih‐Hsin Yang and Yinghui Wang and has published in prestigious journals such as Oncogene, Journal of neurosurgery and Frontiers in Immunology.

In The Last Decade

Yi Su

24 papers receiving 723 citations

Peers

Countries citing papers authored by Yi Su

Since Specialization

Citations

This map shows the geographic impact of Yi Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Su more than expected).

Fields of papers citing papers by Yi Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Su. The network helps show where Yi Su may publish in the future.

Co-authorship network of co-authors of Yi Su

This figure shows the co-authorship network connecting the top 25 collaborators of Yi Su. A scholar is included among the top collaborators of Yi Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi Su. Yi Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Spatiotemporal dynamics of Brucella immune evasion across infection stages 2026 ·Frontiers in Immunology ·Yi Su, (unknown), (unknown), (unknown), (unknown)	0
2	Therapeutic and prophylactic effects of Qipian on COPD in mice: the role of lung and gut microbiota 2025 ·Microbiology Spectrum ·Gwang‐Min Sun, Wanming Hao, Qinghai Li, Yan Ma, (unknown), Yi Su, Xinjuan Yu, Wei Han	2
3	Multi‐sequence MRI‐based clinical‐radiomics models for the preoperative prediction of microsatellite instability‐high status in endometrial cancer 2025 ·PubMed ·Zhuang Li, Yi Su, (unknown), Yong Yin, (unknown), (unknown)	5
4	Discovery of Hydrazineyl Amide Derivative of Pseudolaric Acid B for Reprogramming Tumor-Associated Macrophages Against Tumor Growth 2025 ·Molecules ·Peng Xia, (unknown), Lin Xu, Qinghua Wang, Lin Yang, Yi Su, (unknown), (unknown), Meiyu Geng, Ao Zhang, Lei Zhang, Jing Ai, Chunyong Ding	0
5	A chromosome-level genome assembly for the desert scorpion Mesobuthus przewalskii from Asian drylands 2024 ·Journal of Heredity ·Yi Su, (unknown), Haotian Yang, Cheng‐Min Shi	0
6	Proteomic analysis of mouse liver lesions at all three stages of Echinococcus granulosus infection 2024 ·PLoS neglected tropical diseases ·Nan Jiang, (unknown), (unknown), Yeting Sun, Yi Su, Ying Wang, (unknown), Jianping Cao	1
7	Association between the Reduced Expression of RECK and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease 2024 ·International Archives of Allergy and Immunology ·Jiahui Wang, Yi Su, Hong Liu, (unknown), (unknown), Xinjuan Yu, Qinghai Li, Wei Han	0
8	Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy 2023 ·European Journal of Medicinal Chemistry ·(unknown), Peng Xia, Yinchun Ji, Yi Su, Wenhu Duan, Jing Ai, Hefeng Zhang	1
9	Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities 2023 ·European Journal of Medicinal Chemistry ·Pingyuan Wang, (unknown), Yajing Wang, Shanshan Song, Yong Xi, Xinying Yang, Yanyan Shen, Yi Su, Yiming Sun, Yinglei Gao, Yi Chen, Jian Ding, Ze‐Hong Miao, Ao Zhang, Jin‐Xue He	7
10	ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK 2022 ·Frontiers in Pharmacology ·Peiran Song, Gang Bai, (unknown), Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Yi Ning, (unknown), Yan Fang, Ke Ding, Jian Ding, Hua Xie	0
11	Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy 2020 ·Stem Cell Reviews and Reports ·Fang Liu, Sha Sha, (unknown), Yi Su, Yi-song Xiong, (unknown), Yecheng Li, William Hanes, William Ka Fai Tse	1
12	Correction: Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity 2020 ·Oncogene ·Dongda Zhang, Ning Jin, Weili Sun, (unknown), B. Liu, Zuoquan Xie, Jia Qu, Jianyong Xu, Xue Yang, Yi Su, Sanyi Tang, Hui Han, Dongying Chen, Jian Ding, Minjia Tan, Ming Huang, Meiyu Geng	2
13	Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma 2019 ·Journal of bone oncology ·Shuliang Zhao, Yi Su, Jinghao Duan, Qingtao Qiu, (unknown), Aijie Wang, Yong Yin	48
14	Discovery of JND3229 as a New EGFR^C797S Mutant Inhibitor with In Vivo Monodrug Efficacy 2018 ·ACS Medicinal Chemistry Letters ·Xiaoyun Lu, Tao Zhang, Sujie Zhu, (unknown), (unknown), (unknown), Yan Li, (unknown), Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai‐Hong Yun, Hua Xie, Ke Ding	53
15	Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma 2018 ·Neoplasma ·Wenbin Gong, Yi Su, (unknown), (unknown), Dantong Sun, (unknown), Jinyu Xiang, C.-W. Chi, Ping Sun	19
16	Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models 2017 ·Molecular Cancer Therapeutics ·Jing Ai, Yi Chen, Peng Xia, Yinchun Ji, Yong Xi, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Yuchi Ma, Bing Xiong, Jingkang Shen, Jian Ding, Meiyu Geng	26
17	Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity 2016 ·Oncogene ·Dongda Zhang, Nan Jin, Wei Sun, (unknown), B. Liu, Zuoquan Xie, Jia Qu, Jingjing Xu, (unknown), Yi Su, Shuai Tang, (unknown), Dongying Chen, Jianxun Ding, Minjia Tan, Min Huang, Meiyu Geng	72
18	Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core 2016 ·Bioorganic & Medicinal Chemistry Letters ·Mei Han, (unknown), Yinchun Ji, Zilan Song, Xing Li, Yi Su, Xi‐Sheng Wang, Ao Zhang, Jing Ai, Meiyu Geng	6
19	The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury 2014 ·Cell Death and Disease ·(unknown), (unknown), Yinghui Wang, (unknown), Xuxing Chen, Yi Su, (unknown), Yu Chen, Bing Xiong, James Chih‐Hsin Yang, Jianxun Ding, (unknown)	201
20	Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application 1996 ·Journal of neurosurgery ·Holly Hamilton, David R. Hinton, Ronald E. Law, (unknown), Yi Su, (unknown), Martin Weiß, William T. Couldwell	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact